VANCOUVER, Jan. 31 /CNW/ - Response Biomedical Corporation (TSX-V: RBM,
OTCBB: RPBIF) announced today that the United States Patent and Trademark
Office (USPTO) has issued a Notice of Allowance for the patent, entitled
"Sensitive Immunochromatographic Assay". This patent covers key aspects of
Response Biomedical's lateral flow immunoassays with the RAMP(R) point-of-care
testing platform. The RAMP platform provides highly sensitive and reliable
results, typically in less than 15 minutes.
"The Fong Patent is a very important component of our intellectual
property in the immunoassay space," said Bill Radvak, President and CEO. "The
importance of the RAMP system is that our method of quantitative measurement
allows near laboratory analytical performance in a point-of-care environment,
thus allowing the clinician to make a critical and immediate diagnosis."
This patent has also been issued in Australia and is pending in Europe,
China, Japan, Hong Kong and Canada.
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site
diagnostic tests for use with its portable RAMP Platform for clinical and
environmental applications. RAMP represents a new paradigm in diagnostics that
provides high sensitivity and reliable information in minutes. It is ideally
suited to both point-of-care testing and for laboratory use. The RAMP System
consists of a portable fluorescent Reader and single-use, disposable Test
Cartridges, and has the potential to be adapted to more than 250 medical and
non-medical tests currently performed in laboratories. RAMP clinical tests are
commercially available for the early detection of heart attack and congestive
heart failure. The Company recently filed a submission with the US FDA for
market clearance for its NT-proBNP test, expected to be on the US market in
2007. Sales have already commenced in Europe.
The Company also recently announced a strategic alliance with 3M Company
to commercialize rapid infectious disease tests. Clinical trials for
Staphylococcus aureus and Influenza A/B are now underway, with
commercialization expected in 2007.
In the non-clinical market RAMP tests are currently provided for the
environmental detection of West Nile virus, and biodefense applications
including the rapid on-site detection of anthrax, smallpox, ricin and
botulinum toxin. Several other product applications are under development. The
Company has achieved CE Marking and its Quality Management System is
registered to ISO 13485: 2003 and ISO 9001: 2000.
Response Biomedical is a publicly traded company, listed on the TSX
Venture Exchange under the trading symbol "RBM" and quoted on the OTC Bulletin
Board under the symbol "RPBIF". For further information, please visit the
Company's website at www.responsebio.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
Note on Forward Looking Statements
Statements contained in this press release relating to future results,
events or developments, for example, statements containing the words
"believes," "may," "could", "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects", "goal" and similar expressions, are
"forward-looking statements" or "forward-looking information" under applicable
United States and Canadian securities laws. Forward-looking statements or
information may involve, but are not limited to, comments with respect to our
planned activities, business plan and strategies and their future
implementation, and our expectations for our financial condition and the
results of, or outlook for, our business operations generally. Forward-looking
statements or information are subject to the related assumptions made by us
and involve known and unknown risks, uncertainties and other factors that may
cause actual results, events or developments to be materially different from
those expressed or implied by such statements or information.
Many of such risks, uncertainties and other factors form part of our
underlying assumptions, and include, among other things, our ability to obtain
and enforce timely patent and other intellectual property protection for our
technology and products; our ability to obtain and maintain rights to
technology from licensors; liability for patent, product liability and other
claims asserted against us; commercialization limitations imposed by patents
owned or controlled by third parties; our ability to effectively and
efficiently manage the planned growth of our operations; our ability to
obtain, and the timing of, necessary regulatory approvals; changes in business
strategy or development plans; changes in, or the failure to comply with,
governmental regulations; and other factors referenced in our annual report on
Form 20-F and other filings with Canadian and United States securities
Given these uncertainties, assumptions and risks, readers are cautioned
not to place undue reliance on such forward-looking statements or information.
We disclaim any obligation to update, or to publicly announce any revisions
to, any such statements or information to reflect future results, events or
For further information:
For further information: Response Biomedical Contacts: Bill Wickson,
Manager, Investor Relations, Response Biomedical Corporation, Tel (604)
456-6073, Email: email@example.com; Brian Korb, Vice President, The
Trout Group LLC, Tel: (646) 378-2923, Email: firstname.lastname@example.org